GALAPAGOS - Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity Remains
Recent global collaboration of AbbVie and Galapagos (GLPG) for the Cystic Fibrosis (CF) treatment further reiterates the confidence of AbbVie in GLPG drug discovery platform. GLPG0634 (PhII, oral selective JAK1 inhibitor, partnered with AbbVie for RA) has the best-in-class safety profile and is currently in PhIIb global trials. At ACR 2013, GLPG is going to present 4-week, PhIIa trial results which were consistent for two PhIIA studies - demonstrating that selective JAK1 inhibition by GLPG0634. For more detail, please read our report on GLPG, released on Oct. 4, 2013, titled, 'Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity Remains'.
